Compare OSPN & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSPN | SRZN |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | United States |
| Employees | N/A | 44 |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 390.0M | 356.0M |
| IPO Year | 2000 | N/A |
| Metric | OSPN | SRZN |
|---|---|---|
| Price | $13.15 | $26.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $16.67 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 445.7K | 81.3K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.53% | N/A |
| EPS Growth | ★ 28.77 | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $243,180,000.00 | N/A |
| Revenue This Year | $3.22 | $75.35 |
| Revenue Next Year | $3.16 | N/A |
| P/E Ratio | $42.70 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.07 | $7.45 |
| 52 Week High | $18.13 | $35.00 |
| Indicator | OSPN | SRZN |
|---|---|---|
| Relative Strength Index (RSI) | 75.51 | 41.16 |
| Support Level | $12.33 | $23.95 |
| Resistance Level | $13.38 | $29.18 |
| Average True Range (ATR) | 0.40 | 2.24 |
| MACD | 0.08 | -0.61 |
| Stochastic Oscillator | 92.60 | 14.70 |
OneSpan Inc is a provider of information technology security solutions for banking and financial services and application security markets. The company build secure, seamless, and trusted digital experiences through two solution portfolios: Cybersecurity solutions engaged in protecting identities, securing mobile apps, and safeguarding access through high-assurance authentication, threat intelligence, fraud prevention, and robust mobile app protection, defending users, devices, and applications against sophisticated attacks, while Digital agreement solutions focuses on streamlining workflows with secure e-signatures, identity verification, and smart digital forms, built to enable speed, compliance and other customer experiences.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).